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As a model system of human cardiomyogenesis and for cardiac cell
replacement-based regenerative medicine, pluripotent-to-cardiomocyte
differentiation strategies have recently undergone rapid advancement.
In parallel, strategies for isolating mesoderm cells, a prerequisite lineage
for cardiomyocytes (CMs), have also been under development. Such con-
trolled cell fate speciﬁcation, coupled with differentiation stage-speciﬁc
cell isolation, provides not only an opportunity to describemolecular pro-
grams of cardiomyogenesis, but also an essential tool for investigating
fundamental epigenetic mechanisms.omplications and Metabolism,
pen access article under the CC BY-NPathological cardiac remodeling, often following myocardial infarc-
tion (MI), ismarked by extensive CMhypertrophy and death. As a poten-
tially unlimited cell replacement source, pluripotent-derived-CMs have
been shown to electrically couple with host CMs, promote paracrine
mediated cell survival, and aid widespread cardiac remuscularization
post-MI in non-human primate models (Chong et al., 2014; Carpenter
et al., 2012). hESC-derived-CMs were ﬁrst isolated from regions of spon-
taneous contraction in embryoid bodies (Kehat et al., 2001), and CM
differentiation has since been gradually improved via manipulation of
key developmental pathways including: TGF-β, WNT, hedgehog (HH),
FGF, and Notch signaling, among others (Freire et al., 2014; Lian et al.,
2013). For clinical adoption, fully deﬁned, serum and growth-factor-free
differentiation strategies have evolved to include small molecule mimics
of WNT signal modulators with yields of up to 98% pure CMs (Lian et al.,
2013). Primitive mesoderm (PMESO) has been isolated using the cellC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(CMESO) is known to express PDGFRα (Mummery et al., 2012).
However, most candidate markers are, to variable extents, expressed on
alternative cell types, and distinct lineages can require multiple surface
markers for isolation (Evseenko et al., 2010). To date, no studies have
globally assessed pluripotent-to-CM commitment using puriﬁed
mesoderm cells.
It is widely understood that localized and genome-spanning net-
works of hierarchical epigenetic features dictate nucleosome position-
ing, chromatin architecture, and ultimately the interpretation of the
genetic code. Epigenetic mechanisms, including DNA methylation and
ncRNAs as related to cardiac development and disease, have been
recently reviewed by Tompkins and Riggs (2015). DNA methylation,
or more speciﬁcally 5-methylcytosine (5mc) typically in CpG se-
quences, is essential for normal development, and plays major roles in
X-chromosome inactivation (XCI), imprinting, transposable element
suppression, and tissue-speciﬁc gene expression (Smith and Meissner,
2013). Three enzymes are known to form 5mC, of which DNMT1 is gen-
erally considered the maintenance methyltransferase responsible for
maintaining DNA methylation patterns through replication. DNMT3A
and 3B, on the other hand, exhibit strong de novo activity (Goll and
Bestor, 2005). Three enzymes, TET1, 2, and 3, are now known to actively
demethylate DNA via oxidation of 5mC to 5-hydroxymethylC, which
can be removed by base excision repair enzymes, such as TDG
glycosylase (Kohli and Zhang, 2013). It has become clear that global
DNA methylation patterns are, for the most part, stably maintained.
However, methylation patterns can be dynamically altered during
differentiation and presumably involve de novo methylation, active
demethylation, and restriction of maintenance methylation activities.
The inverse relationship between promoter methylation and gene
expression has been long known, extensively documented (reviewed
by Smith and Meissner, 2013), and recently noted in hESC-derived-
CMs at cardiac structural genes (Gu et al., 2014). In contrast, positive
correlations exist between gene body methylation and expression,
with models favoring transcription coupled DNA methylation and in-
volving DNMT3B (Jjingo et al., 2012; Baubec et al., 2015). Considerable
work remains, however, to comprehensibly understand functional
roles for DNA methylation, especially outside of promoter contexts.
Here, we use a state-of-the art, fully deﬁned and scalable, good
manufacturing practice (GMP)-compliant CM differentiation strategy
and purify PMESO and CMESO cells to improve our understanding of
global DNA methylation patterns over multiple stages of CM differentia-
tion. We address lncRNA, gene expression, and transcription factors
(TFs) that deﬁne human cardiomyogenesis, providing important
genome-wide data sets. Lastly, we observed transcription and differenti-
ation associated exonmethylation to be enriched speciﬁcally at develop-
mental TFs and to persist beyond gene silencing as a transcriptional
“memory” of cellular differentiation.
2. Materials and Methods
2.1. hESC Cultures Through CM Differentiation
From an H7 hESC GMP suspension bank, CMs were derived under
fully deﬁned, GMP compliant conditions (City of Hope, Center for Bio-
medicine and Genetics) (Chen et al., 2012) (Fig. 1a) with adaptations
from Lian et al. (2013).
2.2. Flow Cytometry, Cell Sorting
~2–2.5E5 accutase dissociated cells were washedwith PBS 0.5% BSA,
resuspended in 10 μl of antibody solution (30min at 4 °C),washed again
in PBS with 0.5% BSA (3×) and subjected to ﬂow cytometry. Cell counts
were conducted on a BDAccuri C6 Flow Cytometer (CﬂowPlus). PMESO
and CMESO sortswere performed on a BD FACSARIA II Cell Sorter (FACS
Diva V6.1.3).See supplemental experimental procedures for additional details on
CM differentiation, antibodies used, immunoﬂuorescence, methyl bind-
ing domain (MBD) reactions, MBD-seq and RNA-seq library prepara-
tion, data processing, and validation.
3. Results
3.1. Differentiation of hESCs into PMESO, CMESO, and CMs
To globally describe in vitro human cardiomyogenesis, we prepared
highly pure populations of hESCs, primitive mesoderm (PMESO), cardiac
mesoderm (CMESO), and CMs. Importantly, a scalable GMP suspension
bank of hESCswas coupledwith fully deﬁned, small molecule, GMP com-
pliant differentiation (Fig. 1a). By ﬂow cytometry, N98% of banked hESCs
were positive for pluripotency markers SSEA-4, Tra-1-60, and POU5F1,
whereas, b2% presented SSEA-1, ROR2, and PDGFRα differentiation
markers (Fig. S1a andb). A pilot 31 dayRNA-seq time course demonstrat-
ed progressive downregulation of pluripotency and rapid early upregula-
tion of mesoderm genes from day 1 (D1) to D4, and subsequent delayed
expression of cardiac progenitor (CP) and ﬁnally CM markers (Fig. 1b).
Candidate mesoderm markers ROR2 and PDGFRα peaked from D2 to
D4 andD4 to D6, respectively. Based on these expression patterns, we se-
lected D3 and D4 for isolation of PMESO and CMESO, respectively
(Fig. S1e). Duplicate hESC, PMESO, CMESO, and Percoll density puriﬁed
CM samples (D31) were subsequently prepared as well as D3 ROR2(−)
and D4 ROR2(+)/PDGFRα(−) cells. CM cell fate was conﬁrmed by
synchronized beating activity, N94% cTnT content by FACS (Fig. S1c),
immunoﬂuorescence for cardiac troponin I (cTnI) and myosin heavy
chain 7 (MYH7) (Fig. S1d), and hierarchical clustering of RNA-seq data
with published adult cardiac tissue data (Fig. S1g; (Lindskog et al.,
2015). A double-positive ROR2(+)/PDGFRα(+) sort was used to purify
maturing mesoderm (D4, CMESO) and validated with PMESO (D3) for
target population enrichment (Figs. 1c and S1f).
RNA-seq results demonstrated PMESO cells to be clearly enriched for
early mesoderm and mesendoderm markers and CMESO cells for
CMESO and CP markers (Figs. 1c and S1f). By hierarchical clustering of
all RNA-seq samples, both PMESO and CMESO sub-clustered together
(Fig. S5a), and displayed signiﬁcantly lower residual pluripotent gene
expression,minimal trophoblast and ectoderm gene expression, and in-
creased epithelial-to-mesenchymal transition (EMT) expression (ie:
loss of CHD1, increased TWIST, SNAI2, FN1) (Kovacic et al., 2012). By
CMESO stage, some CM genes were already upregulated (Fig. S1f). Rel-
ative to D3 ROR2(−) cells, PMESO exhibited 1163 differentially
expressed genes (3× fold change, p-value b0.05). By gene ontology
(GO) analysis, upregulated transcripts were clearly enriched for heart
and skeletal system development (mesoderm derivatives; Fig. 1c).
PMESO terms also included: pattern speciﬁcation process (p =
7.53E−15), gastrulation (p = 2.0E−09), and mesoderm development
(p = 1.3E−05) (Table S1). Upregulated CMESO genes, relative to D4
ROR2(+)/PDGFRα(−), were predominately enriched for cardiac devel-
opment terms (1248 differentially expressed genes), showing clear
transition towards CM cell fate. D3 ROR2(−) cells, in distinct contrast,
were enriched for neuron development (p = 1.3E−7; Fig. 1c), and at
D4 ROR2(+)/PDGFRα(−) cells displayed enrichment for multiple
developmental pathways including: endocrine system development
(p = 4.6E−05), neuron differentiation (p = 8.5E−05), and epithelial
cell differentiation (p = 1.4E−04), among others. Taken together, FACS-
based puriﬁcation of PMESO and CMESO populations removes otherwise
contaminant transcriptional, and by extension, epigenetic signatures
from heterogeneous multi-lineage and non-committing cells.
3.2. Dynamic Gene-coding Transcriptional Programs During Stage-speciﬁc
CM Differentiation
To investigate temporal patterns of gene expression over our 4 point
time-series (hESCs, PMESO, CMESO, CM), we used Grid Analysis of
Fig. 1. CM differentiation, sample preparation, and validation. a) Experimental strategy with 4 target populations marked red. Brieﬂy, suspension hESCs were adhered to Synthemax II
plates and CM differentiation induced by CHIR99021 and IWP4. CMs were Percoll density puriﬁed and PMESO and CMESO by FACS. b) Pilot time course of known developmental
markers. Left to right: pluripotent, mesoderm, cardiac progenitor, and CM marker expression. c) Differential expression of PMESO and CMESO compared to D3 ROR2(−) and D4
ROR2(+)/PDGFRα(−), respectively. Black bars = upregulated; gray = downregulated. Top 10 ontology terms are displayed (BP term, EASE p-value).
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ically colors time-series data according to transcript level, grouping
genes with common expression patterns across a 2-dimensional array.
A “snap shot” of PMESO and CM stages of all differentially expressed
genes (2917) is displayed in Fig. 2a. By selecting stage-speciﬁc up or
downregulated transcripts, it becomes evident that CM differentiation
is marked by progressive upregulation of heart development genes
and concomitant downregulation of mitotic and organelle ﬁssion
genes. Pathway speciﬁc regulation of the cell cycle is highlighted in
Fig. S2m. Genes enriched for glycolysis (Table S2; BP: glycolysis) were
suppressed during mesoderm stages, but were generally increased
within CMs which demonstrated massive upregulation of mitochondri-
al oxidative phosphorylation genes (Fig. 2a; Table S2; Fig. S2n–p). Col-
lectively, these observations are well in line with differentiation
associated CM cell cycle exit (Sdek et al., 2011), mitochondrial ﬁssion
gene downregulation, and switches to predominately mitochondrial
oxidative metabolism from anaerobic glycolysis (Chung et al., 2007).
Besides obvious CM stage pathway upregulation (e.g., cardiac muscle
contraction, p= 2.52E−5), cellular component GO demonstrates cardi-
ac structural gene upregulation. Contractile ﬁber,myoﬁbril, I band, Z disk,
A band, and sarcomere were among the most highly enriched terms at
each differentiation stage (Table S2). Lastly, we identiﬁed 289 alterna-
tively spliced genes between CMs and earlier time points. Signiﬁcant
overlap was observed with published results of alternative splicing in
human cardiac precursors (Fig. S3i; (Salomonis et al., 2009)) and tran-
scripts were enriched for functions in muscle tissue development and
contraction. Gene lists and GO results are provided in Table S2 and alter-
native splicing at TPM1 is shown in Fig. S3h.3.3. Transcription Factor and miRNA Regulation of Coding Gene Expression
Wnt, TGF-β, and hedgehog (HH) pathways were signiﬁcantly
enriched among all differentially expressed transcripts over the 4
point time series and in PMESO and CMESO samples relative to alterna-
tive lineage cells (e.g., D3 ROR2(−) and D4 ROR2(+)/PDGFRα(−);
Tables S1 and S2). These critical developmental pathways are intimately
connected (Fig. S2a–c) (Freire et al., 2014) and several distinct
subclasses were uniquely enriched at each differentiation stage
(Figs. 2b–d; S2L).
Differential gene expression was also investigated with GATEs inte-
grated databases of transcription factor (TF) interactions by predicted
protein binding (TFs_predicted_binding_sites.gmt), by prior chromatin
immunoprecipitation (ChIP) studies (TFs_chip_interactions.gmt), and
for miRNA regulation (predicted_microRNAs.gmt). The highest ranked
predicted TF was myocyte-speciﬁc enhancer factor 2 A (MEF2a)
(V$RSRFC4_01; p b 0.0001). MEF2a is preferentially expressed at
PMESO and CMESO stages, highly upregulated in CMs (Figs. 2e, S1f,
S2d), and positively correlated with predicted target gene expression.
In contrast, polycomb complex (PRC) 1 member, polyhomeotic
homolog I (PHCI), was preferentially silenced over CM commitment
and inversely correlated with target gene expression (Figs. 2f and
S2e). The ~13 fold reduction in PMESO, relative to hESCs and D3
ROR2(−) cells (Fig. S1f), is consistent with a developmental repressive
PHC1 function. Both MEF2a and PHC1 targets are involved in CM
development and contraction functions; the highest ranked GO term
for MEF2a and PHC1 were striated muscle tissue development (p =
1.27E−5) and heart development (p = 3.3E−15), respectively
Fig. 2.Differential expression during hESC-to-CM commitment. a) “Snap shot” of PMESO and CM stages by GATE visualization and top 5 ontology terms for up- and downregulated genes
(BP term, EASEp-value). Hexagons are individual genes clustered by temporal differentiation expressionpatterns. Redhexagons=upregulated; green=downregulated. b–d) Expression
hierarchical clustering of Wnt (b), TGF-β (c), and HH (d) pathway genes. Most individual sub-clusters were clearly deﬁned by stage-speciﬁc expression (i.e., early, late) and individual
genes were colored based on enrichment in PMESO and/or CMESO stages relative to alternative lineage cells. At PMESO and/or CMESO, red genes= enrichment; green genes= suppres-
sion; no color = no or unclear enrichment. Scale = row z-score. e–f) Expression distribution of predicted MEF2a (e) and PHC1 (f) targets during CM differentiation. Center lines =me-
dians; box limits=25th and 75th percentileswithwhiskers extended1.5× the interquartile range from those percentiles (R software); outliers=open circles. (*p b 0.05;Mann–Whitney
U-test). Blue dashed lines =MEF2a (E) and PHC1 (F) expression.
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repressive PHC1, miR-302/367 silencing-marked differentiation, was
enriched in alternative lineage cells, and was inversely correlated with
strong target gene induction (Fig. S2h–k).
3.4. lncRNA Associations with Coding Gene Transcription
lncRNAs, deﬁned as non-coding transcripts N200 bp in length, have
previously been reported to be expressed at lower levels than coding
genes (Cabili et al., 2011; Chakraborty et al., 2014). If we consider N1
FPKM as an expressed transcript, it is clear that relative to the wide ex-
pression range of coding genes, most lncRNA expression falls within a
narrow range (N1 and b10 FPKM) with subtle range widening by CM
stage (Figs. 3a and S5h). In general, hESC-to-CM differentiation wasmarked by increasing densities of expressed coding genes and to a
lesser extent lncRNAs, and decreasing proportions of silent coding
genes (FPKM b 1). lncRNAs paired in cis with the nearest coding gene
were hierarchically clustered, and a number of sub-clusters emerged
with clear stage-speciﬁc enrichment or exclusion (Fig. 3b). For each
sub-cluster, a positive correlation exists between lncRNAs and cis paired
coding gene expression (Fig. 3c). For these lncRNA associated genes, the
highest ranked GO term was cell fate determination (p = 0.004) and
~15% of lnc-associated genes were classiﬁed under regulation of tran-
scription, DNA dependent (53/370; p = 0.004). In line with the high tis-
sue speciﬁcity of lncRNAs (Cabili et al., 2011), numerous cis-associated
developmental TFs were identiﬁed, including MEIS1 and 2 (Fig. 3d),
TBX2 (Fig. 5G), GATA3 (Fig. 6c), and BMP4 (Table S4). Differentiation-
induced lncRNA-coding gene pairs are also involved in cell adhesion
Fig. 3. lncRNA expression and CM differentiation. a) The frequency of FPKM values (density proﬁle) for coding and lncRNA gene expression was plotted for each differentiation stage
(expanded in Fig. S5h). b) Hierarchical clustering of lncRNAs by expression. Scale = row z-score. c) Stage-speciﬁc lncRNA sub-clusters were correlated with nearest cis matched
coding gene expression. Box plots display paired coding gene expression (Fig. 2f for box plot description). d) Positive association of lncRNA (MEIS1-AS3) and higher levelMEIS1 expression.
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CDK10, CCND1), and overall, results suggest stage-speciﬁc lncRNA
expression to be functionally correlated with coding genes regulating
key aspects of CM differentiation.
3.5. Global DNA Methylation Patterns and CM Differentiation
To investigate both global and region speciﬁc DNA methylation
features of CM differentiation, methyl binding domain (MBD)-seq was
conducted for hESCs, PMESO, CMESO, and CMs. We ﬁnd that CG island
(CGI) methylation progressively increases during CM differentiation,
with lncRNA genes harboring elevated CGI methylation relative to cod-
ing genes (Fig. 4a). DNAmethylationwasmapped to a compositemodel
of all annotated transcripts, and both lncRNA and coding genes were
observed to be hypomethylated at TSS-centered promoters (Fig. 4b).
For both species, promoter methylation was inversely correlated with
expression, but lncRNA genes on average were signiﬁcantly more
methylated through promoter and intragenic regions (Figs. 4b, S4c–d).
Coding and lncRNA genes transiently lost methylation upstream of the
TSS and within intragenic regions at mesoderm stages, notably more
so for CMESO lncRNA genes. This observation extended into mesoderm
methylation losses at SINE and Alu repetitive elements. By contrast, sat-
ellite elements increased methylation throughout differentiation
(Fig. 4d). Likely reﬂecting CM cell cycle exit (Fig. 2a),DNMT1 expression
dropped signiﬁcantly from CMESO-to-CM stages (Fig. 4e). DNMT3A ex-
pression approximately doubles from hESCs-to-PMESO and converges
with pronounced DNMT3B downregulation. Although lower DNMT3B
de novo methyltransferase activity may be responsible for transient
mesoderm hypomethylation, it is striking that TDG DNA glycosylase ismaximally expressed at PMESO and CMESO stages and SMUG1
glycosylase at CMESO, accompanying dynamic changes in TET gene
expression (Fig. 4f). These results suggest targeted DNA demethylation
to be a natural feature of mesoderm and CM differentiation.
3.6. Differential DNA Methylation and CM Differentiation
Differentially methylated regions (DMRs) were identiﬁed between
samples (see supplemental experimental procedures), annotated and
quantiﬁed by genomic location, assessed for genomeand gene ontology,
and correlated with gene expression. DMRs numbered the highest
between CMESO-to-CM stages (11,236,27 days), yet even the single
day PMESO-to-CMESO transition resulted in 5380 DMRs. Thus DNA
methylation at earlier stages of differentiation is particularly dynamic.
DMR-based genome ontology results overall reﬂect CM differentiation
(e.g., CMESO-CM = cardiac muscle cell differentiation, p = 3.7E−14;
see Table S5 and Fig. S3a). Genes were quantiﬁed for DMR gains or
losses within deﬁned regions (promoters, exons, introns, etc), and
consistent with global methylation trends, demonstrated a bias for
PMESO-to-CMESO hypomethylation and CMESO-to-CM hypermethyla-
tion (Fig. S3b).
CM hypermethylated promoter DMRs, relative to preceding time
points, were associated with decreasing or restrained gene expression
and hypomethylated DMRs with increasing gene expression (Figs. 5a;
S3c, OCT4, Nanog). By CM stage, the median expression of genes with
promoter methylation gains was 5.04 fold lower than those with meth-
ylation loss (p b 0.05). Promoter regulation extended across functional
gene groups involved in CM development, structure, and contraction
(Fig. 5b). Both methylation gains (p = 0.03) and losses (p = 0.018)
Fig. 4. Global methylation and CM commitment. a) Percent CGI methylation over differentiation. Methylated CGI =MBD/input ratio of greater than 1.5 across the island. b) Normalized
methylation enrichmentwas plotted across promoter, gene body, and downstream bins representing a compositemodel of coding or lncRNA genes. c) Hierarchical clustering of promoter
methylation and gene expression. Genes or lncRNAs differentially expressed over differentiation were clustered by expression (Exp) and matched MBD-seq values (Me) for promoter
window−5 kb to +1 kb of the TSS. Scale = row z-score. d) Bar graph of total MBD-seq reads mapped to each repetitive element e) Expression of DNA methyltransferases and f)
demethylation pathway members by differentiation stage.
79J.D. Tompkins et al. / EBioMedicine 4 (2016) 74–85were enriched for heart development; whereas, the top ranked GO term
was contractile ﬁber (hypo, p = 6.75E−5), complementing muscle cell
contraction (p = 6.52E−3) and correlating with massive CM stage up-
regulation (Fig. 5b). CMhypermethylated promoterswere also enriched
for basolateral plasma membrane (p = 4.0E−3), hypomethylated pro-
moters for focal adhesion pathway (p = 6.1E−3), and both gains and
losses at cell adhesion promoters (Fig. 5b). CMPromoter DMRs therefore
also reﬂect fundamental changes in cell architecture, including cell–cell
and cell-extracellular matrix interactions that are known to occur over
hESC-to-CM differentiation. CM promoter hypomethylation at cardiac
muscleMYH6 andMHY7 is displayed in Fig. 5c.
Consistent with global expression results, several WNT, HH, and
TGF-β genes also underwent promoter methylation changes, with the
latter pathway being CM stage hypomethylated and upregulated
(Fig. 5b). Differentially methylated WNT and HH genes tended to
acquire promoter methylation post-transient mesoderm induction
(Figs. 5b and S3d) and often harbor gene body DMRs as well
(Fig. S2a–c). Methylation changes among pathway members may also
interface with expected cell cycle (Table S6, CMESO hypo, M
phase; p = 3.7E−2) and apoptotic regulation with connections to
Rho-Rock signaling as cells differentiate and approach terminal states
(Fig. S2a–c, expanded in Fig. S3e).
3.7. Gene Body Methylation and Expression
We and others have previously observed positive correlations
between intragenic DNA methylation levels and gene expression,
although this strong, positive correlation only holds up tomid-level ex-
pression and actually inverts at highly expressed genes (Tompkins et al.,2012; Jjingo et al., 2012). These observations are highly consistent with
transcription coupledmethylation activity. It remains unclear, however,
whether elevated transcription activity and dense RNAPII occupancy in-
hibits linked methylation deposition (Jjingo et al., 2012) and/or if
targeted demethylation is requisite to maximum transcription (Veloso
et al., 2014; Baubec et al., 2015). Here, both CM intragenic methylation
DMR gains and losses were positively correlated with differentiation
associated increases in gene expression (Fig. 5d). Yet, consistent with
transcription linked DNA methylation, intragenic methylation gains
tend to occur at genes expressed at low levels during preceding differ-
entiation stages, whereas methylation losses tend to occur at genes al-
ready expressed at moderate levels at prior stages. These observations
in the context of transcription associated histone modiﬁcations are
revisitedwithin the discussion. GO results also suggest geneswith intra-
genicmethylation changes have roles in CMdifferentiation and function
including 66 TFs (regulation of transcription, p= 2.7E−4, Table S6). Top
rankedGO terms for CMexonmethylation gains and losseswere cell ad-
hesion (p = 4.7E−9) and induction of apoptosis, respectively (1.4E-2).
For introns, these terms were ion transport (hypermethylation, p =
3.7E−5) and intracellular signaling cascade (hypomethylation, 2.9E-5),
respectively. Differential intragenic methylation at the focal adhesion
pathway is also expanded (Fig. S3f–g).
In higher eukaryotes regulation of splicing is enigmatic, but recent
evidence has implied a role for DNA methylation. Evidence suggests
that splicing may be co-transcriptional and involve epigenetic interpre-
tation, nucleosome positioning, and/or involve the recruitment of chro-
matin binding proteins including DNA methylation associated binding
of MeCP2 (Maunakea et al., 2013; Lev Maor et al., 2015). In our study,
we see clear evidence for both alternative splicing (Fig. S3h-l and
80 J.D. Tompkins et al. / EBioMedicine 4 (2016) 74–85Table S2) and differential intragenic methylation changes over CM dif-
ferentiation, and further, alternatively spliced genes are overrepresent-
ed among genes with DMRs (Fig. S3j). However, the overwhelming
majority of genes with intragenic DMRs show no evidence for splicing,
and exon methylation changes among alternatively spliced genes do
not signiﬁcantly occur (Fig. S3k). Although our results imply a connec-
tion between differential methylation and splicing, a direct methylation
change to splicing event correlation was not identiﬁed.3.8. Exon Methylation as a “Memory” of Developmental History
Similar to CM promoter methylation gains, exon hypermethylated
DMRs were also enriched at embryonic morphogenesis (p = 4.3E–8)
and heart development (9.9E-3) genes. As many CM exon methylated
genes were observed to also have undergone promoter methylation
(35.2% overall; 126/358), this presented an opportunity to investigate
“dual methylation” events for correlations with gene expression
(Fig. 5e). For embryonic morphogenesis genes with exon methylation
gains, 11/22 also gained promoter methylation (Fig. 5f; Table S6; p =
2.1E−3). TBX1 and TBX2 provide clear examples. Both underwent pro-
gressive and extensive differentiation associated exon methylation and
yet had widely divergent promoter and gene expression activity
(Fig. 5g). As such, promoter hypermethylation with resulting reduction
of transcription, appears to override otherwise positive intragenic
methylation correlations with gene expression (Fig. 5e–f). This inter-
pretation however, raises an important question regarding transcrip-
tion coupled DNA methylation: How can one explain exon
methylation gains in the absence of transcription? With this in mind,
we re-examined gene expression at 7 additional time points between
hESC and PMESO and CMESO and CM stages, focusing on gene sets un-
dergoing exon hypermethylation by CM stage (Fig. 6a and b). Genes
were re-sampled with increased stringency, requiring exon DMR gains
in CMs versus hESCs and PMESO or CMESO. Of the resulting 48 exon
methylated candidates, most were developmental TFs and most were
transcriptionally induced late in differentiation, positively correlating
CM exon methylation with transcription (Fig. 6a). Given these candi-
dates, we also interrogated the aforementioned 66 TFs from CM exon
hypermethylated DMRGO results (Table S6; Fig. 6b). Thesemethylation
changes were independent of gene splicing (Fig. S3l, legend) and al-
though a signiﬁcant portion of CM exon methylated genes were down-
regulated or silenced by this stage (~1/2 of TFs), virtually all (92%; 105/
114), including TBX1,were expressed at FPKMN 1 duringdifferentiation
(by comparison, 16,873/41,495 or 40.7% of all annotated genes
exceeded 1 FPKM). Merely the timing of expression had fallen between
CMESO and CMmethylation sampled time points. This collectively indi-
cates that 1) exon methylation is generally correlated with elevated
gene transcription during CM differentiation and 2) exon methylation
can persist beyond the time of gene silencing marking developmental
history. Residual exon methylation “memories” were enriched speciﬁ-
cally among developmental TFs. Examples span from expected exon-
expression correlations (Fig. 5g-TBX2, Fig. 6c-TBX3, CBX4, FZD1) to
those silenced by CM stage and harboring transcriptional methylation
“traces” (Fig. 5c-SHH, SP6, GATA2, GATA3, FOXF2). This “exon methyla-
tion memory” was also observed among the HOX genes, in which the
HOXB cluster was uniquely expressed over CM differentiation and wasFig. 5. Differential DNA methylation and CM commitment. a) All CM promoter DMRs by hyp
(Table S6) were assessed for gene expression over CM differentiation. For all box plots in this
promoter hypomethylation at cardiac structural genes. Light green = promoter. MYH6 is o
several exons. Light blue = bisulﬁte sequencing validation region. Rows of circles represen
validation at TBX2 is shown in panel g. d–f) Expression distribution of genes with multiple t
coding DNA sequence exon DMRs for ontology and gene expression correlations. d) All CM e
gains compared to those with CM exon gains, but lacking promoter hypermethylation DMRs
(Table S6). g) TBX1 (restrictive promoter methylation gain) and TBX2 (permissive methylati
RNA-seq data at MYH6 and TBX2 genes, which undergo differential methylation. Both qRT-P
change relative to PMESO time point. For these genes, there was no detectable ampliﬁcation
and d.the only HOX cluster with signiﬁcant exon methylation, including per-
sistent methylation beyond gene silencing (Fig. S4a and b).
4. Discussion
4.1. CM Differentiation Strategies for the Clinic
Pluripotent-derived-CMs promise an unlimited source of replace-
ment cells for cardiac regeneration. In this report, we have utilized a
fully deﬁned, xeno-free, scalable GMP suspension hESC bank, and driv-
en differentiation by small molecule WNT signal manipulation under
deﬁned and GMP compliant conditions. Such culture strategies are a
pre-requisite to realizing clinical potential (Chen et al., 2012;
Tompkins et al., 2012) and were built through manipulation of
established regulators of cardiac development (e.g., Wnt signaling). In
this study, scalability aided FACS puriﬁcation of PMESO and CMESO
cells for global transcription and DNA methylation studies and has pro-
vided a rich resource of candidate transcription factors, lncRNAs, and
miRNAs, that represent a next generation of targets for improving the
efﬁciency and perhapsmaturity of derived CMs. As a next step for wide-
spread clinical use, ongoing pre-clinical work is focused on a similar, but
entirely suspension-based CM differentiation protocol.
4.2. Puriﬁcation of Target Cell Populations for Genome-wide Studies
Mesoderm puriﬁcation is a necessary step towards more clearly un-
derstanding human cardiomyogenesis and may also prove useful in the
treatment of cardiac pathologies. For the latter, other groups have ob-
served that relatively immature CMs or progenitors improve transplant
engraftment, with evidence for in vivo maturation (Carpenter et al.,
2012; Fujimoto et al., 2011; Tompkins and Riggs, 2015), and therefore,
transplantation of PMESO or CMESO isolatesmight also improve cell re-
tention and mediate pro-survival paracrine signaling in vivo.
Two groups, Paige et al. (2012) (hESCs-to-CMs) andWamstad et al.
(2012) (mESCs-to-CMs) have proﬁled global histonemodiﬁcations and
gene expression in prior studies of CM differentiation. However, cellular
heterogeneity, including ﬁnal CM preparations that were ~25–30%
cTnT(−) cells, signiﬁcantly confounded epigenomic results (Parmacek
and Epstein, 2013). Here, we can estimate that at minimum, 26% of D3
cells would be ROR2(−), 30% of D4 cells ROR2(+)/PDGFRα(−), and
21% of D31 cells (ﬁnal CM time point) cTnT(−) (Fig. S1c–e). These po-
tential contaminants were removed and found to contain both non-
committing and multi-lineage differentiating cells (Fig. 1c; Table S1).
By comparison, in hESC-to-CM studies, Paige et al. speciﬁcally noted
the presence of smoothmuscle and endothelial cells in CMpreparations
with a minimum of 50% cTnT+ CMs in sample preparations for
genome-wide studies (Paige et al., 2012). Nonetheless, several impor-
tant features of cardiomyogenesis were observed. Among key ﬁndings
were the activation of Wnt, HH, and TGFβ gene families, similar to our
results, as well as differentiation associated increases in transcription
coupled with increased promoter H3K4me3 and TSS downstream
H3K36me3. These modiﬁcations are well known to correlate with de-
creased promoter DNA methylation and increased intragenic DNA
methylation (Baubec et al., 2015; Morselli et al., 2015; Paige et al.,
2012), respectively, in agreement with results from our study.er- or hypomethylation and b) those corresponding to selected enriched ontology terms
ﬁgure, see Fig. 2f for methods. The color legend in panel a applies to all box plots. c) CM
ne of the most highly expressed CM genes and hypomethylation extends into the ﬁrst
t consecutive CpG sites of individual sequences. Black circles = methylated. Additional
ypes of CM gene body DMRs. Annotated 5′ and 3′ UTR exon DMRs were combined with
xon or intron DMRs by methylation change. e and f). Dual promoter-exon methylation
for all genes and f) for CM exon methylated genes enriched for embryonic morphogenesis
on loss) exhibit differentiation associated intragenic hypermethylation. H) Validation of
CR and RNA-seq data are normalized to internal control TPTI and expressed as log2 fold
of transcripts from hESCs. qRT-PCR data for all RNA-seq samples is provided in Fig. S5c
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Wamstad et al. (2012) observed that lncRNA expression in mESC-
derived-CMs positively correlates with cis paired coding geneexpression, and we extend this here for hESC-to-CM differentiation
(Fig. 3c). Aided by PMESO and CMESO puriﬁcation, we ﬁnd that the
overwhelming majority of examined lncRNAs are enriched unambigu-
ously by differentiation stage, in line with known high tissue-speciﬁc
82 J.D. Tompkins et al. / EBioMedicine 4 (2016) 74–85lncRNA expression (Fig. 3b) (Cabili et al., 2011). Unique expression
within PMESO and CMESO populations suggests functional roles within
CM development (e.g., linc-MEIS1-1, linc-MEIS2-2, linc-BMP4-1, etc) and
this logic was also applied to identify key signaling pathway members
(Fig. 2b–d), TF targets (Fig. S2d–e), and miRNAs (Fig. S2h–k). These re-
sults provide a diverse array of major candidate sets for future function-
al genetic and epigenetic manipulation studies of CM development and
disease. Although functional lncRNA roles in murine cardiac develop-
ment have been identiﬁed (Fatica and Bozzoni, 2014; Klattenhoff
et al., 2013), the poor conservation betweenmouse and human lncRNAs
(Ulitsky et al., 2011) and the dysregulation of lncRNA expression in
human cardiomyopathies (Papait et al., 2013), strengthen further the
importance of identifying lncRNAs speciﬁc to human cardiomyogenesis.
4.4. lncRNAs and DNA Methylation
Both lncRNA and coding genes exhibit a negative correlation be-
tween promoter methylation and gene expression and generally posi-
tive correlations between gene body methylation and expression
(Figs. 4c and S4d). Interestingly, lncRNA genes exhibit higher methyla-
tion at TSS centered regions, at CGIs, and across intragenic regions
(Figs. 4a–b, S4c–d). Higher TSS centered methylation relative to coding
genes is consistent with the lower average expression of lncRNAs
(Fig. 3a) and the well known inverse relationship between promoter
methylation and transcription. With regards to intragenic methylation,
lncRNAs have little overall expression range and therefore increases to
gene body methylation with increasing expression percentiles, though
evident, become muted relative to the wide intragenic methylation
and expression range of coding genes (Figs. 3a and S4d). Recent identi-
ﬁcation and annotation strategies for describing lncRNAs have been
necessarily improving, addressing complexities associated with
handling diverse arrays of lncRNAs at a variety of overlapping genomic
elements. In the future, our data can be revisited to identify novel
lncRNAs, lncRNA subtype distributions, and functional correlations
with distinct methylation events. Indeed, some lncRNAs are speciﬁcally
associated with common features involving DNA methylation such as
CGI, repetitive element, imprinting methylation, and MeCP2 binding
(Forne et al., 1997; Chakraborty et al., 2014; Nan et al., 1997; Cabili
et al., 2011) and physical associations may exist between DNMTs and
lncRNAs (Wang et al., 2015).
4.5. DNA Methylation, Transcription, and Development
DNA methylation changes, both increases and decreases, occur
throughout development and it is nowwell established that a combina-
tion of maintenance, de novo, and demethylating activities are required
for propermethylation distribution both globally and speciﬁcallywithin
promoters, enhancers, and gene bodies. Highlighting the essential role
for DNA methylation in mammalian development, Dnmt1−/−mouse
embryos die shortly after gastrulation and Dnmt3b −/− or Dnmt3a
−/−mice die at embryonic day 9.5 and shortly after birth, respectively
(Jurkowska et al., 2011). Deletion of DNMT1 is not tolerated in hESCs
(which are more epiblast like than mESCs), and Dnmt1 −/− mESCs
die upon differentiation. Interestingly, in mESCs (Jurkowska et al.,
2011; Takebayashi et al., 2007), and recently demonstrated in hESCs
(Liao et al., 2015), neither DNMT3A nor DNMT3B are required for ESC
viability, but additional passaging of Dnmt3a or Dnmt3b knockout ESCs
is associated with global hypomethylation and prevents differentiation.
Both de novo transferases display considerable global binding redun-
dancy and target SINE and LINE elements (Jin et al., 2011), but Liao
et al. (2015) observed that DNMT3B knockout hESCs speciﬁcally lose
satellite element methylation. However we ﬁnd that despite virtual
DNMT3B silencing by CM stage, satellite element methylation is highest
in CMs where DNMT3A expression, but not 3B, predominates (Fig. 4d–
e). Although the speciﬁcity of DNAmethyltransferases and demethylase
enzymes is limited (e.g., CpG or 5mC), speciﬁcity for extendedsequences is directed by chromatin structure and/or speciﬁc cofactors,
which can include lncRNAs as well as transcription factors (Smith and
Meissner, 2013). Future studieswill continue to delineate themolecular
details of DNA methylation regulation and will no doubt be aided by
tracking methylation dynamics through cellular differentiation.
4.6. Histone Methylation, Transcription, and Gene Body Methylation
Recently a clear connection between histonemethylation and intra-
genic DNA methylation has been established in which de novomethyl-
transferase DNMT3B binds H3K36me3, which marks regions of active
transcription (Morselli et al., 2015; Baubec et al., 2015), and this may
help explain positive correlations between gene body methylation
gains and increasing gene transcription (Fig. 5d). Morselli et al. (2015)
have shown in yeast, which normally has no 5mC, that H3K36me3 in-
troduced by SET2 histone methyltransferase dictates the location of
DNA methylation by recruiting DNMT3B (exogenously introduced).
This same study shows that H3K4me3, which is located preferentially
at active promoters, strongly prevents DNMT3B recruitment. Thus,
DNMT3B activity and resulting methylation patterns are strongly inﬂu-
enced by intragenic H3K36 methylation patterns. Our working hypoth-
esis is that transcription of both coding and lncRNA genes leads to an
increase in H3K36me3 by action of SET2 histone methyltransferase
and this in turn leads to an increase in DNA methylation over the
transcribed region. Therefore, transcription coupled DNA methylation
requires preceding H3K36me deposition. At high transcription levels
the transcribed region can become less methylated (ex: MYH6, but
not MYH7 in Fig. 5c), but we assume that this is by a different mecha-
nism that applies to relatively rare, highly transcribed regions
(Fig. S5f). Reduced exon methylation in highly expressed genes might
be due to tandem RNAPII blocking of maintenance methylation activity
(Jjingo et al., 2012), or increased active demethylation. Indeed, the TET
enzymes, TDG, and SMUG1 glycosylases are generally induced upon
CM differentiation with the glycosylases transiently peaking at CMESO
stage and corresponding to transient hypomethylation within gene
bodies (Fig. 4b and f).
4.7. Exon Methylation, Transcriptional “Memory Traces” and Development
The linking of intragenic methylation with transcription likely ex-
plainswhy gene bodyDNAmethylation is a better predictor of cell iden-
tity than promoter methylation (Illingworth et al., 2010). In this study,
we observed CM hypermethylated DMRs to be enriched at exons of de-
velopmental TFs, includingmany TBOX (TBX1-5) andmany HOXB clus-
ter genes. Of the 4 HOX clusters, only HOXB became hypermethylated
within the CM lineage and, strikingly, aside from low level HOXA1 tran-
scription, we observe only the HOXB cluster to be expressed (Figs. S4a–
b; 6b). These and other developmental genes (Fig. 6) were observed to
maintain exon methylation post-gene silencing, in effect establishing a
transcriptional “memory.” These transcription factor genes may be
uniquely protected during re-establishment of the methylome in the
inner cell mass of early embryo and the establishment of the cell line.
Further, hESCs are known to be more epiblast-like than naïve mESCs
(Liao et al., 2015), so it remains possible that an examination of a
more naïve hESC linewould yield additional candidate genes exhibiting
transcriptional “traces” at earlier developmental windows.
How persistent is transcription linked exon methylation after tran-
scription is reduced or stopped? Why do we see this phenomenon
enriched at developmental TFs? These are important questions for
future studies, however, study of evolutionary sequence changes have
already demonstrated that “pro-epigenetic” selection has functioned
to preferentially preserve CG sites in coding regions of HOX and other
master developmental genes, as well as the retention of CGI clusters
near these genes (Branciamore et al., 2010). Indeed, exon methylation,
not promoter or CGI methylation, is over evolutionary time the most
highly conserved feature of the DNA methylation system, conserved in
Fig. 6. Exon methylation as a transcriptional “trace.” a) 46 high stringency CM exon methylated genes were clustered by expression. 2/48 candidate genes had FPKM values b1 at every
sampled time point and were removed. b) CM exon hypermethylated DMRs functionally enriched for regulation of transcription. 7/66 were ﬁltered out prior to clustering (1 pseudogene
and 6 FPKM b 1 at all sampled time points). Hierarchical clustering by correlation with centroid linkage, gene ordering by peak time (dChIP, 2010.01; (Li, 2008)). Scale = standardized
expression level. c) Examples of exon methylation as a “memory” of developmental transcription history. GATA3, FOXF2, SHH, SP6, and GATA2 are repressed by CM stage, the latter 3
being promoter hypermethylated. Gray = regions of intragenic methylation gains; green = promoter regions. Blue RNA-seq data = CMESO-CM intervening time points. Red box =
GATA3 associated lncRNA expression.
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bees where it is involved in the control of queen bee development
(Lyko et al., 2010). Further, TF binding sites are rich within gene bodies,
tend to be GC rich, often overlap CGIs, and many TFs display distinct
methyl DNA binding afﬁnities (Deaton and Bird, 2011). This raises thepossibility that exon methylation “memories” serve to maintain global
TF distributions, support chromatin networks, and additionally regulate
cryptic promoters or enhancers. For the latter possibility, these ele-
ments are also enriched among CG-rich gene bodies and highlight a
long-standing idea that intragenic DNA methylation may reduce
84 J.D. Tompkins et al. / EBioMedicine 4 (2016) 74–85transcriptional noise, including antisense transcription (Deaton and
Bird, 2011; Illingworth et al., 2010). Although this does not explain all
intragenic methylation (Jjingo et al., 2012), like conventional gene pro-
moters, gene body promoters are subject to DNAmethylation silencing.
Therefore, an attractive possibility is that developmentally important
switches can be stabilized by the exon methylation system. For exam-
ple, transcription through an intragenic, potentially active promoter,
will result is methylation of that promoter and thereby prevent inap-
propriate antisense and sense transcription. Such a system seems to
have value for establishing stable cell states.
DNAmethylation epigenetic “memories” have been described previ-
ously, but the focus was on promoter methylation. For example, during
iPSC generation the incomplete erasure of somatic epigenetic marks, in-
cluding promoter DNA methylation, constitute a residual “memory” of
somatic tissue origins. As these “memories” are lost with additional
iPSC passaging, it is likely that they simply reﬂect incomplete iPSC
reprogramming (Kimet al., 2010).Well before these concepts, however,
and still widely accepted today, DNAmethylation is thought to “lock-in”
stably silent states at promoters and repetitive elements (Razin and
Riggs, 1980). Though we again observe promoter methylation to be as-
sociated with gene silencing (Figs. 4c, 5a–c, e–g, 6c) this is not a reﬂec-
tion of preceding transcriptional activity. Importantly, our results
suggest that onemust now consider exonmethylation as a likely player
in cellularmemory. These “exonmemories” reﬂect preceding transcrip-
tion and as such raises the possibility that developmental or pathologi-
cal history might be predicted from exon methylation patterns. Indeed,
heart failure is marked by the reactivation of improper fetal develop-
mental gene networks (reviewed by Tompkins and Riggs, 2015) and
the hijacking of developmental programs is a common feature of
many cancer types. For example, HOX cluster CGI hypermethylation
marks patients with coronary heart disease (Nazarenko et al., 2015)
and is frequently observed in cancer (Shah and Sukumar, 2010). Insight
into the transcriptional disease etiology through “exon memory” stud-
ies may prove to be quite powerful in understanding and treating
these conditions.
In closing, the replacement of lost CMswill be required for cardiac re-
generative medicine strategies and the scalability of pluripotent cell
sources, including suspension cultures, offers an unlimited cell replace-
ment source in cardiacmedicine. This naturally hinges on researcher con-
trolled CM differentiation, which continues to improve, and as
highlighted in this report also provides an essential in vitro model of
human cardiac muscle development. Here, the multi-stage global analy-
sis of hESC differentiation provides a comprehensive understanding of
CM generation through the lenses of transcription and epigenetic pat-
terns and led to observations of transcription “memories” in CMproducts.
Data generated from this study is available through NCBI's Gene
Expression Omnibus (GEO) through GEO series accession number
GSE76525 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=
GSE76525). Authors declare no conﬂict of interest.
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